All Data
Lead Product(s): W0180,Pembrolizumab
Therapeutic Area: Oncology Product Name: W0180
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
W0180 is a first-in-class antibody targeting VISTA (V-domain Ig suppressor of T cell Activation). VISTA is a negative checkpoint regulator of T cell response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UCARTCS1
Therapeutic Area: Oncology Product Name: UCARTCS1
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
Cellectis worked closely with the FDA over the past months, to address the agency’s requests, which include adjustments to the MELANI-01 clinical protocol designed to enhance patient safety.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
NBTXR3 activated by radiation therapy produced a strong abscopal effect without a checkpoint inhibitor combination. NBTXR3 activated by radiation therapy stimulated adaptive antitumor immunity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT033
Therapeutic Area: Oncology Product Name: MaaT033
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
MaaT033 is an oral, full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic. Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide,Nivolumab
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
Data show that, to date, administration of NBTXR3 via intra-tumoral injection has been feasible and well tolerated in all patients (head and neck cancer, lung metastasis, and liver metastasis).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients with advanced solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): UCART22
Therapeutic Area: Oncology Product Name: UCART22
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
BALLI-01 is a Phase 1 open-label dose-escalation study designed to assess the safety, the maximum tolerated dose (MTD), and preliminary anti-leukemia activity of UCART22 in patients with R/R B-ALL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and immunotherapy .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OSE-172,BI 754091
Therapeutic Area: Oncology Product Name: BI 765063
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
BI 765063 (OSE-172) is the first selective antibody antagonist of SIRPα-mediated “Don’t Eat Me” signals. BI 765063 is currently being evaluated in a Phase 1 trial conducted in patients with advanced solid tumors studied in combination with Boehringer Ingelheim’s BI 754091.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hafnium dioxide,Undisclosed
Therapeutic Area: Oncology Product Name: NBTXR3
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Phase I Study of Intratumoral NBTXR3 in Combination with anti-PD-1 in Patients with Advanced Cancers will be presented at the conference.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
